Merck Reports Updated Results of Keytruda (pembrolizumab) in P-III KEYNOTE-062 Study as a Monotherapy for 1L Treatment of Advanced Gastric Cancer

 Merck Reports Updated Results of Keytruda (pembrolizumab) in P-III KEYNOTE-062 Study as a Monotherapy for 1L Treatment of Advanced Gastric Cancer

Merck Reports Updated Results of Keytruda (pembrolizumab) in P-III KEYNOTE-062 Study as a Monotherapy for 1L Treatment of Advanced Gastric Cancer

Shots:

  • The P-III KEYNOTE-062 (NCT02494583) study involves assessing of Keytruda as monothx. and in combination with CT (cisplatin/5-fluorouracil/capecitabine) & CT as monthx. in 763 patients for the 1L treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
  • The P-III KEYNOTE-062 results: as monothx. met its 1EPs, noninferior to CT; as a combination therapy, no superiority for OS & PFS compare to CT as monothx.; no new safety signals observed; presented at ASCO on Jun 02, 2019
  • Keytruda (pembrolizumab, IV, 100mg) is a mAb blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2 and activating the T lymphocytes and is evaluated in 950+ trials for multiple indications

Click here to read full press release/ article | Ref: Merck | Image: Caixin Global

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post